HOSHI IRYO-SANKI CO., LTD.
7634・Standard Market・Wholesale Trade
Medical Gas-related Business
The founding business and a core segment that supports the Group's stable earnings base.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (full year, fiscal year under review) | ¥3,944 million | ¥4,002 million | ↓ |
| Segment profit (full year, fiscal year under review) | ¥461 million | ¥635 million | ↓ |
| Segment assets (full year, end of fiscal year under review) | ¥1,719 million | ¥1,673 million | ↑ |
| Depreciation (full year, fiscal year under review) | ¥157 million | ¥145 million | ↑ |
| Capital expenditures (increase in tangible/intangible fixed assets, fiscal year under review) | ¥242 million | ¥324 million | ↓ |
Business Details
This segment manufactures and sells Medical Oxygen Gas, Anesthetic Gas, and Other Medical Gases generally. Manufacturing is handled by multiple subsidiaries, while the Company handles sales and planning, forming a vertically integrated business structure. Oxygen supply to medical institutions is a lifeline directly connected to sustaining patients' lives, and stable supply on a 24-hour, 365-day basis is a social responsibility. In FY2026 (ending March 2026), net sales were ¥3,944 million and segment profit was ¥461 million.
Recent Overview
Shipment volumes were steady, but rising costs caused segment profit to deteriorate sharply, down 27.4% year on year.
In FY2026 (ending March 2026), net sales were ¥3,944 million (down 1.5% year on year) and segment profit was ¥461 million (down 27.4% year on year). Although shipment volumes of Medical Oxygen and Medical Carbon Dioxide trended steadily, rising material and procurement prices due to higher energy costs and shipping expenses reflecting global conditions significantly pressured profit. The Company advanced negotiations to shift to appropriate pricing while also working to expand human resources in preparation for the logistics and transportation industry's response to the post-2024 issue.
Key Products
Growth Drivers
- Maintaining the sales base through steady shipment volumes of Medical Oxygen and Medical Carbon Dioxide
- Passing on cost increases through negotiations to shift to appropriate pricing
- Strengthening organizational structure and expanding human resources in response to the logistics and transportation industry's post-2024 issue
- Promoting a strategy of cost reduction through in-house production and expanding sales volume through new customer development
- Strengthening relationships with existing customers by reinforcing the stable supply system to medical institutions
Risks
- Profit pressure from rising energy costs, material costs, and procurement prices (segment profit down 27.4% year on year in FY2026 (ending March 2026))
- Increased costs from soaring logistics and transportation costs and response to the post-2024 issue including driver shortages
- Risk of delayed pass-through of appropriate pricing due to difficult price negotiations with medical institutions
- Risk of increased manufacturing costs at manufacturing subsidiaries due to rising operating costs (fuel costs, electricity costs, etc.)
- Risk of further increases in energy and raw material prices due to fluctuations in global conditions
Last updated: June 24, 2026